OncoMatch/Clinical Trials/NCT06563388
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Is NCT06563388 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for oligometastasis.
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Colorectal Cancer
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: allowed if completed >3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) and recovered from adverse events
Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier
Cannot have received: radiotherapy
Exception: allowed if completed >3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) and recovered from adverse events; prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints
Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Roswell Park Comprehensive Cancer Center · Buffalo, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06563388 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify